HTEC to Support Digital Telco Enabler Telness Tech in Platform Software Development
17.9.2024 19:31:00 EEST | Business Wire | Press release
Telness Tech, a fast-growing international software company founded in Sweden, and HTEC, a global end-to-end digital product development and engineering services company, are pleased to announce their work on Telness Tech’s innovative platform, which will support the company’s ongoing expansion into new markets, like the US.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240917678716/en/
In this partnership, HTEC will support Telness Tech by providing additional engineering expertise for the new platform’s deployment, customization, and user migration from legacy platforms. HTEC will also assist in the development of business-to-consumer (B2C) applications and various network integrations, including building an abstraction layer for easier integrations. (Graphic: Business Wire)
The platform’s proprietary software is a cloud-based, end-to-end solution for mobile virtual network operators (MVNOs) that offers comprehensive operations and business support system (OSS/BSS) capabilities. It streamlines and automates the customer journey, deploying quickly and remotely without the need for traditional telco infrastructure or legacy IT systems. The platform has already helped Telness Tech clients boost customer ratings in Europe.
In the partnership, HTEC will support Telness Tech by providing additional engineering expertise for the new platform’s deployment, customization, and user migration from legacy platforms. HTEC will also assist in the development of business-to-consumer (B2C) applications and various network integrations, including building an abstraction layer for easier integrations.
Commenting on the collaboration, HTEC’s Director of Engineering & Delivery Bojan Šukalo said:
“Recent tech innovations have transformed how we communicate, but many in the telco industry still use traditional infrastructure. With HTEC’s technical expertise and engineering capacity, we’re perfectly positioned to support the industry’s digital transformation and aligned with Telness Tech to steer the industry forward.”
Founder and COO of Telness Tech, Jonas Cedenwing, highlighted the value of HTEC’s support in this expansion:
“With high demand for our software across the globe, partnering with HTEC ensures that our clients’ platform demands and transitions remain smooth and streamlined, enabling us to continue our high expansion rate without compromising quality.”
About Telness Tech
Founded in Sweden with offices in the US, Telness Tech provides everything needed to launch or run a fully automated mobile operator. The company’s end-to-end BSS/OSS solutions streamline customer journeys, provisioning, and porting — necessary functions to run a digital mobile operator. As a result, satisfied clients drastically reduce operational costs.
About HTEC
HTEC Group Inc. is a global premium technology services firm powering the technological evolution of the world’s most impactful organizations—from disruptive startups to the Fortune 500. HTEC combines deep engineering expertise with remarkable creativity, enabling its customers to innovate, design, and develop disruptive technologies and new digital solutions across different industries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917678716/en/
Contacts
HTEC Media Relations: media@htecgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom